Journal Home
Search for

Volume 49, Issue 1, Pages 71-74 (January 2010)


View previous. 20 of 32 View next.

V-Y Fasciocutaneous Advancement Flap Coverage of Soft Tissue Defects of the Foot in the Patient at High Risk

Thomas S. Roukis, DPM, PhD, FACFAS1Corresponding Author Informationemail address, Monica H. Schweinberger, DPM, AACFAS2, Valerie L. Schade, DPM, AACFAS3

published online 01 July 2009.

Abstract 

This single-center, observational case series involved a review of prospectively collected data pertaining to 16 V-Y fasciocutaneous advancement flaps performed on 16 consecutive patients between August 2006 and December 2008. Each patient underwent primary excision of a foot ulcer with debridement of soft tissue and bone, insertion of polymethylmethacrylate antibiotic–loaded bone cement, and immobilization. At an average of 3 days after the index procedure, soft tissue and osseous deformities were corrected in 13 of the 16 patients, and a V-Y fasciocutaneous advancement flap was used for coverage of the soft tissue defect in all patients. Patients were kept nonweightbearing and were followed up until clinical healing occurred or failure was declared. There were 12 male and 4 female patients with a mean age of 64.0 ± 7.4 years (range, 48–75 years). Fifteen patients had diabetes mellitus with a mean of 5.1 ± 1.8 (range, 3–8) medical comorbidities. There were 10 medial forefoot, 3 central forefoot, 2 lateral forefoot, and 1 dorsal midfoot full-thickness soft tissue defects that displayed a mean diameter of 2.3 ± 1.4 cm (range, 1.0–3.5 cm). All but 4 flaps healed primarily, with each developing marginal dehiscence that healed with local wound care measures. Two deep infections occurred despite healing of the flap, which necessitated transmetatarsal amputation with split-thickness skin graft coverage. When properly performed and after complete resolution of infection, V-Y fasciocutaneous advancement flap coverage of complex foot ulcerations represents a useful and reliable technique even in patients with multiple medical comorbidities.

Level of Clinical Evidence4

1 Chief, Limb Preservation Service, Vascular/Endovascular Surgery Service, Department of Surgery, Director Limb Preservation Complex Lower Extremity Surgery and Research Fellowship, Madigan Army Medical Center, Tacoma, Washington

2 Former Fellow, Limb Preservation Complex Lower Extremity Surgery and Research Fellowship, Limb Preservation Service, Vascular/Endovascular Surgery Service, Department of Surgery, Madigan Army Medical Center; Podiatric Surgeon, VA Medical Center, Cheyenne, Wyoming

3 Fellow (PGY-5), Limb Preservation Complex Lower Extremity Surgery and Research Fellowship, Limb Preservation Service, Vascular/Endovascular Surgery Service, Department of Surgery, Madigan Army Medical Center, Tacoma, Washington

Corresponding Author InformationAddress for correspondence: Thomas S. Roukis, DPM, PhD, FACFAS, Chief, Limb Preservation Service, Vascular/Endovascular Surgery Service, Department of Surgery, Director Limb Preservation Complex Lower Extremity Surgery and Research Fellowship, Madigan Army Medical Center, 9040-A Fitzsimmons Dr, MCHJ-SV, Tacoma, WA 98431.

 Disclaimer: The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Army or the Department of Defense.

 Financial Disclosure: None reported.

 Conflict of Interest: None reported.

PII: S1067-2516(09)00191-4

doi:10.1053/j.jfas.2009.04.006


View previous. 20 of 32 View next.